CDLX Nasdaq Services-Computer Programming, Data Processing, Etc. Financials FY2016βFY2025
Cardlytics, Inc. had $233M of revenue in fiscal 2025, down 16.2% on the year before. Over five years, revenue changed +4.5% a year on average.
Last close Β· Oct 23, 2026
$1.80
3.7%Hi! I read Cardlytics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β16.2%
No. Sales fell 16.2% last year.
Does it make a profit?
β44.4%
No. It lost money last year.
Does profit turn into cash?
3.8%
Partly. 3.8% of sales ends up as free cash.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Cardlytics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 7, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 4, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 5, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 7, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 12, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 6, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Cardlytics, Inc. had $233M of revenue in fiscal 2025, down 16.2% on the year before. Over five years, revenue changed +4.5% a year on average. Its operating margin was β43.6%, up 26.6Β pts: of every 100 in sales, about β44 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Cardlytics, Inc. lost $103M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $8.8M in fiscal 2025, 3.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Cardlytics, Inc. owes $160M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Cardlytics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $233M | $122M | $91.8M | $65.6M | $48.7M |
| Debt incl. finance leases | $184M | $226M | $258M | $259M | $209M |
| Debt / equity | 0.3x | 1.1x | 1.9x | 3.7x | β |
| Interest coverage | β9.7x | β114.4x | β21.9x | β22.0x | β |
| Current ratio | 1.1x | 1.0x | 1.3x | 1.2x | 1.8x |
| Quick ratio | 1.1x | 1.0x | 1.3x | 1.2x | 1.8x |
| Total assets | $1.3B | $691M | $574M | $393M | $286M |
| Total liabilities | $573M | $480M | $439M | $323M | $292M |
| Shareholders' equity | $691M | $212M | $135M | $70.0M | β$6.5M |
| Net debt (β = net cash) | β$49.1M | $104M | $166M | $194M | $160M |
KIRA Β· Its return on capital was β52.3%: every 100 invested in the business earned about β52 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Cardlytics, Inc. passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 3 / 8 | 5 / 8 | 2 / 8 | 3 / 8 | 2 / 8 | 4 / 8 | 2 / 8 | 5 / 8 |
| Accruals ratio | β | 2.4% | β26.8% | β15.1% | β14.8% | β10.7% | β42.1% | β21.3% | β37.3% | β33.3% |
| Altman Z'' | β | β8.42 | β4.98 | β0.15 | 1.45 | β0.57 | β8.58 | β6.97 | β13.43 | β17.09 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $113M | $130M | $151M | $210M | $187M | $267M | $299M | $309M | $278M | $233M |
| Net interest income | β$6.2M | β$8.2M | β$3.3M | β$0.5M | β$3.0M | β$12.6M | β$2.6M | β$2.3M | β | β |
| Research and development | $13.9M | $12.2M | $16.2M | $11.7M | $17.5M | $38.1M | $54.4M | $51.4M | $49.6M | $39.8M |
| Operating income | β$56.2M | β$17.1M | β$40.9M | β$17.3M | β$53.9M | β$123M | β$458M | β$136M | β$195M | β$102M |
| Interest expense | β | β | β | β | $3.3M | $12.7M | $4.0M | $6.2M | $8.9M | β$10.6M |
| Pretax income | β$75.7M | β$19.6M | β$53.0M | β$17.1M | β$55.4M | β$136M | β$467M | β$135M | β$189M | β$103M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β$7.9M | β$1.4M | $0.0M | $0.0M | $0.0M |
| Net income | β$75.7M | β$19.6M | β$53.0M | β$17.1M | β$55.4M | β$129M | β$465M | β$135M | β$189M | β$103M |
| Net income to common | β$76.7M | β$25.4M | β$53.2M | β$17.1M | β$55.4M | β$129M | β$465M | β$135M | β | β |
| Diluted EPS | β$32.48 | β$7.86 | β$2.79 | β$0.72 | β$2.04 | β$3.99 | β$13.92 | β$3.69 | β$3.91 | β$1.95 |
| Diluted shares | 0.00B | 0.00B | 0.02B | 0.02B | 0.03B | 0.03B | 0.03B | 0.04B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | β$32.5M | β$22.1M | β$19.0M | $11.5M | β$7.6M | β$38.5M | β$53.9M | β$0.2M | β$8.8M | $9.3M |
| Capital expenditure | $1.8M | $1.2M | $5.9M | $8.3M | $5.4M | $3.1M | $1.2M | $0.7M | $1.6M | $0.5M |
| Free cash flow | β$34.3M | β$23.3M | β$24.9M | $3.2M | β$13.0M | β$41.6M | β$55.1M | β$0.9M | β$10.4M | $8.8M |
| Depreciation and amortization | $4.2M | $3.0M | $3.3M | $4.5M | $7.8M | $29.9M | $37.5M | $26.5M | $25.7M | $25.2M |
| Stock-based compensation | $3.4M | $5.1M | $26.8M | $15.9M | $32.4M | $50.3M | $44.7M | $41.0M | $40.4M | $28.1M |
| Acquisitions | β | β | β | $0.0M | $0.0M | $494M | $2.3M | $0.0M | $0.0M | β |
| Share buybacks | β | β | β | β | $0.0M | $0.0M | $40.0M | $0.0M | $0.0M | β |
| Dividends and buybacks | β | β | β | β | $0.0M | $0.0M | $40.0M | $0.0M | $0.0M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $22.8M | $21.3M | $39.6M | $104M | $293M | $233M | $122M | $91.8M | $65.6M | $48.7M |
| Total debt | β | $57.0M | $46.7M | $0.0M | $174M | $184M | $226M | $258M | $259M | $209M |
| Finance lease liabilities | β | β | β | β | $0.0M | β | β | β | β | β |
| Current assets | β | $74.6M | $124M | $196M | $386M | $359M | $250M | $224M | $178M | $137M |
| Current liabilities | β | $42.1M | $51.9M | $78.4M | $81.3M | $327M | $249M | $171M | $149M | $78.4M |
| Property and equipment, net | β | $7.3M | $10.2M | $14.3M | $13.9M | $11.3M | $5.9M | $3.3M | $2.6M | $1.9M |
| Goodwill | β | β | β | β | $0.0M | $743M | $353M | $277M | $159M | $110M |
| Intangible assets | β | $0.5M | $0.4M | $0.4M | $0.4M | $126M | $53.5M | $35.0M | $11.4M | $5.6M |
| Total assets | β | $101M | $154M | $224M | $423M | $1.3B | $691M | $574M | $393M | $286M |
| Total liabilities | β | $309M | $102M | $81.0M | $265M | $573M | $480M | $439M | $323M | $292M |
| Shareholders' equity | β$217M | β$209M | $52.0M | $143M | $157M | $691M | $212M | $135M | $70.0M | β$6.5M |
| Margins | ||||||||||
| Operating margin | β49.8% | β13.1% | β27.2% | β8.2% | β28.9% | β45.9% | β153.3% | β43.9% | β70.2% | β43.6% |
| EBITDA margin | β46.1% | β10.8% | β25.0% | β6.1% | β24.7% | β34.7% | β140.8% | β35.3% | β61.0% | β32.8% |
| Net margin | β67.1% | β15.1% | β35.2% | β8.1% | β29.7% | β48.1% | β155.8% | β43.6% | β68.0% | β44.4% |
| FCF margin | β30.4% | β17.9% | β16.5% | 1.5% | β7.0% | β15.6% | β18.4% | β0.3% | β3.7% | 3.8% |
| Net interest share of revenue | β5.5% | β6.3% | β2.2% | β0.3% | β1.6% | β4.7% | β0.9% | β0.8% | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β54.8% | β35.2% | β112.2% | β15.1% | β114.5% | β35.7% | β58.5% | β52.3% |
| Return on capital employed | β | β29.2% | β40.2% | β11.9% | β15.8% | β13.1% | β103.5% | β33.7% | β80.2% | β49.1% |
| Return on equity | β | β | β | β17.6% | β36.9% | β30.3% | β103.1% | β77.8% | β184.9% | β326.0% |
| Return on assets | β | β19.5% | β41.7% | β9.1% | β17.1% | β15.2% | β47.6% | β21.3% | β39.2% | β30.5% |
| Return on tangible equity | β | β | β103.1% | β12.0% | β35.4% | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | 15.6% | 15.6% | 39.6% | β11.2% | 42.9% | 11.8% | 3.6% | β10.0% | β16.2% |
| FCF growth | β | β | β | β | β509.0% | β | β | β | β | β |
| Share count change | β | 36.8% | 490.1% | 24.6% | 14.6% | 18.3% | 3.8% | 9.2% | 32.5% | 9.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | 0.9x | 0.0x | 1.1x | 0.3x | 1.1x | 1.9x | 3.7x | β |
| Interest coverage | β | β | β | β | β16.2x | β9.7x | β114.4x | β21.9x | β22.0x | β |
| Current ratio | β | 1.8x | 2.4x | 2.5x | 4.7x | 1.1x | 1.0x | 1.3x | 1.2x | 1.8x |
| Quick ratio | β | 1.8x | 2.4x | 2.5x | 4.7x | 1.1x | 1.0x | 1.3x | 1.2x | 1.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.6% | 0.9% | 3.9% | 3.9% | 2.9% | 1.2% | 0.4% | 0.2% | 0.6% | 0.2% |
| Stock comp / revenue | 3.1% | 3.9% | 17.8% | 7.5% | 17.3% | 18.8% | 15.0% | 13.3% | 14.5% | 12.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 3.0 | 5.0 | 2.0 | 3.0 | 2.0 | 4.0 | 2.0 | 5.0 |
| Altman Z'' | β | β8.4 | β5.0 | β0.2 | 1.4 | β0.6 | β8.6 | β7.0 | β13.4 | β17.1 |
| Accruals ratio | β | 2.4% | β26.8% | β15.1% | β14.8% | β10.7% | β42.1% | β21.3% | β37.3% | β33.3% |
Source: SEC EDGAR XBRL filings (CIK 0001666071). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
